NIH Budget Cuts May Slow Personalized Cancer Drugs, Group Says
This article is for subscribers only.
Development of personalized cancer treatments tailored to the molecular makeup of individual tumors may be jeopardized by little-changed or reduced U.S. funding for biomedical research, according to a new report.
The American Association for Cancer Research instead recommends an 8.6 percent increase in the National Institutes of Health fiscal 2012 budget, to $33.3 billion. The Philadelphia-based group, the world’s largest cancer research organization, is responding to a $322 million cut to the NIH this year.